SCHEDULE 13G/A: EcoR1 Capital and Affiliates Maintain Significant Stake in Tango Therapeutics

EcoR1 Capital, LLC, along with its affiliates and control person Oleg Nodelman, has reported a continued beneficial ownership of 9.9% in Tango Therapeutics, Inc. as of December 31, 2024.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Tango Therapeutics, Inc.
• As of December 31, 2024, EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 10,630,736 shares of Common Stock, representing 9.9% of the class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 10,022,411 shares, representing 9.3% of the class.
• The percentages are calculated based on 107,417,818 shares of Common Stock outstanding on November 1, 2024, as reported in Tango Therapeutics' Form 10-Q for the quarter ended September 30, 2024.
• All reported shares are held with shared voting and shared dispositive power.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a significant institutional investor is maintaining a substantial stake in the company, indicating continued confidence. The filing also explicitly states the investment is for ordinary course of business, not control, which can be viewed positively by the market.

Positives

• A significant institutional investor, EcoR1 Capital, and its affiliates maintain a substantial stake (9.9%) in Tango Therapeutics, indicating continued confidence in the company.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a long-term investment perspective rather than activist intent.

Future Outlook

NA

Industry Context

This filing reflects a significant investment by a specialized healthcare/biotech fund, EcoR1 Capital, in Tango Therapeutics, a biotechnology company. Such substantial stakes by institutional investors are common in the biotech sector, where long-term capital is often required for drug development and clinical trials. The continued holding of a near-10% stake suggests EcoR1's ongoing belief in Tango Therapeutics' potential within the competitive biotechnology landscape.

Stakeholder Impact

• Shareholders: The continued significant stake by a major institutional investor may be viewed positively, potentially signaling stability and long-term confidence in the company's prospects.

Key Dates

Keywords

Tango Therapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology Investment, Institutional Investor